Track topics on Twitter Track topics that are important to you
Kangpu Biopharma of Shanghai completed a first-in-human US Phase I trial of KPG-818, a small molecule immunomodulator based on the CRBN E3 ubiquitin ligase complex. Kangpu expects KPG-818 will be an effective treatment for systemic lupus erythematosus (SLE) and hematological malignancies. In the Phase I trial, which was conducted in healthy participants, KPG-818 did not show any safety or tolerability problems. Kangpu, formed by returnees, is developing novel small molecule drugs for cancer, autoimmune and inflammatory disorders. More details....
Share this with colleagues:
Original Article: Kangpu Completes Phase I Trial of Cancer ImmunomodulatorNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...